公开(公告)号：US20220056125A1

公开(公告)日：2022-02-24

申请号：US17405275

申请日：2021-08-18

Applicant: Cephalon, Inc.

Inventor： Anna Mikaela BRACKEN ,  Adam CLARKE ,  Bridget A. COOKSEY ,  Anthony Gerard DOYLE ,  Mark Terence LIDDAMENT ,  Matthew POLLARD ,  Lynn POULTON ,  Anna Maria Matilda QUIGLEY ,  Julia ROZENFELD ,  Marta SZABAT

IPC: C07K16/28 ,  A61P35/04 ,  A61P17/10 ,  A61P29/00

Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human PAR-2 and compositions comprising such antibodies or antigen-binding fragments thereof. In a particular aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human PAR-2 block the interaction between a PAR-2 activating ligand and an extracellular domain of PAR-2, and/or blocks PAR-2 activation by a PAR-2 activating ligand, In further aspects, the antibodies or antigen-binding fragments can be used to treat diseases or conditions associated with increased expression of PAR-2 and/or diseases or conditions that can be alleviated by antagonizing activation of PAR-2 by a PAR-2 activating ligand (e.g., airway diseases, skin diseases, cancer, orofacial granulomatosis, inflammatory conditions, and pain associated with various diseases or conditions).

公开(公告)号：US20200270339A1

公开(公告)日：2020-08-27

申请号：US16471616

申请日：2017-12-21

Applicant: Cephalon, Inc.

Inventor： David Jose Simon LAINE ,  Matthew POLLARD ,  Anthony Gerard DOYLE ,  Lynn Dorothy POULTON ,  Adam William CLARKE

IPC: C07K16/24 ,  A61P1/00 ,  A61P3/00 ,  A61P37/00 ,  A61P29/02

Abstract: Recombinant antibodies that specifically bind to IL-15 as well as a complex of IL-15 and the IL-15 Receptor-alpha are provided. The antibodies inhibit immune cell proliferation, and are capable of use in the treatment of any autoimmune or inflammatory disease or condition where IL-15 is dysregulated, including Celiac disease.

公开(公告)号：US20220127352A1

公开(公告)日：2022-04-28

申请号：US17647082

申请日：2022-01-05

Applicant: Cephalon, Inc.

Inventor： David Jose Simon LAINE ,  Matthew POLLARD ,  Anthony Gerard DOYLE ,  Lynn Dorothy POULTON ,  Adam William CLARKE

IPC: C07K16/24 ,  A61P37/00 ,  A61P3/00 ,  A61P29/02 ,  A61P1/00

Abstract: Recombinant antibodies that specifically bind to IL-15 as well as a complex of IL-15 and the IL-15 Receptor-alpha are provided. The antibodies inhibit immune cell proliferation, and are capable of use in the treatment of any autoimmune or inflammatory disease or condition where IL-15 is dysregulated, including Celiac disease.